mitomycin has been researched along with Cancer of Pancreas in 199 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer." | 9.14 | Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009) |
| "This study evaluates the maximum tolerated dose (MTD) and activity of mitomycin, docetaxel, and irinotecan (MDI) regimen on metastatic pancreatic adenocarcinoma, previously treated with gemcitabine-containing chemotherapy." | 9.11 | Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. ( Bonetto, E; Di Carlo, V; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Ronzoni, M; Staudacher, C; Villa, E; Zerbi, A, 2004) |
| " The dose-limiting toxicities at the 160 mg/m2 gemcitabine level were myelosuppression, specifically neutropenia +/- thrombocytopenia, and gastrointestinal symptoms, including stomatitis, vomiting, and diarrhea." | 9.09 | Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. ( Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H, 2001) |
| "In a randomized trial we compared single-agent epirubicin with the FEM (5-fluorouracil/epirubicin/mitomycin) combination in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas." | 9.07 | Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. ( Coombes, RC; Glees, J; Topham, C, 1993) |
| "Twenty-two patients with inoperable adenocarcinoma of the pancreas were treated with 5-fluorouracil (5-FU), mitomycin C (Mito-C), and 1(-2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU)." | 9.06 | Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. ( Chapman, J; Chinn, B; Groshko, G; Maniscalco, B; Piper, D; Reznik, S; Vaughn, C; Ward, D, 1989) |
| "Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)." | 9.05 | MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984) |
| "To report the effect of regional combination chemotherapy in a cohort of patients with inoperable pancreatic carcinoma treated with or without low-dose warfarin." | 7.73 | Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. ( Löhr, M; Müller, H; Nakchbandi, IA; Nakchbandi, W; Singer, MV, 2006) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 6.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer." | 5.14 | Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009) |
| "In contrast to earlier reports HAP and CAI with MMC and Melphalan did not demonstrate any benefit in terms of tumour response, median survival and pain reduction, compared to less invasive treatment options." | 5.11 | Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for locally advanced pancreatic cancer: a phase I-II trial. ( de Bruijn, EA; Eggermont, AM; Guetens, G; Jeekel, J; ten Hagen, TL; van Eijck, CH; van Etten, B; van IJken, MG, 2004) |
| "This study evaluates the maximum tolerated dose (MTD) and activity of mitomycin, docetaxel, and irinotecan (MDI) regimen on metastatic pancreatic adenocarcinoma, previously treated with gemcitabine-containing chemotherapy." | 5.11 | Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. ( Bonetto, E; Di Carlo, V; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Ronzoni, M; Staudacher, C; Villa, E; Zerbi, A, 2004) |
| " The dose-limiting toxicities at the 160 mg/m2 gemcitabine level were myelosuppression, specifically neutropenia +/- thrombocytopenia, and gastrointestinal symptoms, including stomatitis, vomiting, and diarrhea." | 5.09 | Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. ( Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H, 2001) |
| "In a randomized trial we compared single-agent epirubicin with the FEM (5-fluorouracil/epirubicin/mitomycin) combination in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas." | 5.07 | Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. ( Coombes, RC; Glees, J; Topham, C, 1993) |
| "One hundred thirty-three patients with advanced pancreatic adenocarcinoma and measurable disease were treated with 5-fluorouracil (5-FU) plus doxorubicin plus mitomycin C (FAM), streptozotocin plus mitomycin C plus 5-FU (SMF) in the regimen originally reported, and streptozotocin plus mitomycin C plus 5-FU with 5-FU and streptozotocin administered in five-day courses." | 5.06 | Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. ( , 1986) |
| "One hundred eighty-seven patients with histologically proven advanced pancreatic adenocarcinoma were randomly assigned to therapy with 5-fluorouracil (5-FU) alone, to the Mallinson regimen (combined and sequential 5-FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C), or to combined 5-FU, doxorubicin, and cisplatin (FAP)." | 5.06 | A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. ( Barlow, JF; Cullinan, S; Foley, JF; Kardinal, CG; Krook, JE; Moertel, CG; Norris, BD; Schutt, AJ; Tschetter, LK; Wieand, HS, 1990) |
| "Twenty-two patients with inoperable adenocarcinoma of the pancreas were treated with 5-fluorouracil (5-FU), mitomycin C (Mito-C), and 1(-2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU)." | 5.06 | Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. ( Chapman, J; Chinn, B; Groshko, G; Maniscalco, B; Piper, D; Reznik, S; Vaughn, C; Ward, D, 1989) |
| "Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)." | 5.05 | MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "We aimed to evaluate the efficacy and safety of 5-fluorouracil-based neoadjuvant chemoradiotherapy (NACRT) in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC)." | 3.91 | Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. ( Abe, Y; Aiura, K; Endo, Y; Fukada, J; Hori, S; Itano, O; Kitagawa, Y; Kitago, M; Masugi, Y; Nakano, Y; Oshima, G; Shinoda, M; Yagi, H, 2019) |
| "In patients with known BRCA 1 or 2 mutation-associated pancreatic adenocarcinoma, the addition of a DNA cross-linking agent such as cisplatin, oxaliplatin, or mitomycin to a standard gemcitabine chemotherapy backbone should be considered." | 3.77 | A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. ( Drukker, L; Epstein, A; Gabizon, A; Isacson, R; Keinan, A; Kelsen, D; Lowery, M; O'Reilly, EM; Rachkiman, M; Reissman, P; Rosengarten, O; Segal, A; Shah, MA; Smyth, E, 2011) |
| "For patients with locally advanced gastric cancer, combined-modality therapy has resulted in long-term survival for approximately 15% of cases." | 3.75 | The role of chemotherapy in the management of gastric and pancreatic carcinomas. ( Schein, PS, 1985) |
| "To report the effect of regional combination chemotherapy in a cohort of patients with inoperable pancreatic carcinoma treated with or without low-dose warfarin." | 3.73 | Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. ( Löhr, M; Müller, H; Nakchbandi, IA; Nakchbandi, W; Singer, MV, 2006) |
| "(1) To determine the toxicity of an intensified postoperative adjuvant regimen for periampullary adenocarcinoma (pancreatic and nonpancreatic) utilizing concurrent 5-fluorouracil (5-FU), leucovorin (LV), dipyridamole (DPM), and mitomycin-C (MMC) combined with split-course locoregional external beam radiotherapy (EBRT) to 50 Gy." | 3.70 | Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Donehower, RC; Grochow, LB; Hruban, RH; Hurwitz, H; Jaffee, EM; Korman, LT; Lillemoe, KD; O'Reilly, S; Yeo, CJ; Zahurek, ML, 2000) |
| "From November 1983 to January 1993, 30 patients with pancreatic adenocarcinoma including 9 with carcinoma of the body and tail were treated by a multimodal approach consisting of extended pancreatectomy, intraoperative radiotherapy (IORT), and hepatic artery or portal vein infusion of mitomycin C (MMC) followed by systemic bolus injection." | 3.70 | Long-term survival after multimodality treatment for resectable pancreatic cancer. ( Fukushima, N; Kinoshita, T; Kosuge, T; Mukai, K; Ozaki, H; Shimada, K; Tokuuye, K; Yamamoto, J, 2000) |
| "In order to determine whether preresectional chemoradiotherapy (CTRT) would influence resectability, local control, and survival of patients with localized pancreatic adenocarcinoma, a 5 1/2-year prospective study of 39 patients treated with preoperative radiation therapy, 5-Fluorouracil (5-FU), and Mitomycin C has been performed." | 3.68 | A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. ( Agarwal, P; Eisenberg, BL; Engstrom, P; Hoffman, JP; Litwin, S; Paul, AR; Scher, R; Solin, LJ; Watts, P; Weese, JL, 1993) |
| "We investigated the antitumor effects of intratumoral (IT) injection of mitomycin-C (MMC), 5-fluorouracil (5FU), adriamycin (ADR), cisplatin (CDDP), streptozotocin (STZ), and interleukin-2 (IL-2) on well-differentiated pancreatic ductal adenocarcinoma (WD PaCa), a solid tumor model in the Syrian golden hamster." | 3.68 | Experimental study on multidisciplinary treatment of pancreatic cancer. ( Makino, I; Moriai, T; Takeba, T, 1990) |
| " In our previous studies with human gastrointestinal and breast cancers xenografted into nude mice, combination therapy with mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) [I] or cisplatin (CDDP), vindesine (VDS) and 5'-DFUR [II] produced higher response rates than single-agent therapy with any one of these drugs." | 3.67 | [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T; Yamauchi, T, 1987) |
| "Hexamethylmelamine, mitomycin C and 5-fluorouracil infusion (HexMF) achieved a median survival of 9 months for the 45 patients with either metastatic stage III or unresectable stage II carcinoma of the pancreas." | 3.67 | Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion. ( Bruckner, HW; Butwell, N; Gorbaty, MI; Kalman, J; McKenna, A; Spigelman, M; Storch, J, 1989) |
| "A 55-year-old female, in which an unresectable Borrmann II-type gastric cancer (moderately differentiated adenocarcinoma) extending from vicinity of the cardia to the lower portion of the corpus, with direct invasion into the pancreas and extensive lymph node metastases, confirmed by laparotomy, was treated postoperatively by 3 courses of chemotherapy with cisplatinum in combination with mitomycin C and 5-fluorouracil." | 3.67 | Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil. ( Azuma, S; Furuta, T; Kawata, R; Ohashi, H; Saji, S; Sakata, K; Shimokawa, K; Suzuki, M; Tanemura, H, 1988) |
| "Nineteen patients with unresectable and metastatic adenocarcinoma of the pancreas and ampulla of Vater were treated with intermittent regional infusion of the celiac axis (CAI) with the combination of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin (FAM-S)." | 3.66 | Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study. ( Bukowski, RM; Hewlett, JS; Livingston, RB; Theodors, A; Weick, JK, 1982) |
| "In gemcitabine-pretreated pancreatic cancer, salvage chemotherapy has not been established, and the prognostic factors are not completely known." | 2.76 | Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lee, KH; Lim, KH; Oh, DY, 2011) |
| "Once developed, the progression of pancreatic cancer metastasis is virtually unstoppable with current therapies." | 2.76 | Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. ( De Jesus-Acosta, A; Donehower, R; Eshleman, JR; Garrido-Laguna, I; Hidalgo, M; Hruban, RH; Jones, S; Klein, A; Laheru, D; Maitra, A; Rajeshkumar, NV; Villarroel, MC, 2011) |
| " Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
| "The incidence of liver metastasis in group A was 34% which was lower than 50% in group B." | 2.74 | Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. ( Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ, 2009) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 2.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "Mitomycin C (MMC) in combination with infusional 5-fluorouracil (FU) plus folinic acid (FA) is an effective treatment for metastatic gastrointestinal cancer." | 2.71 | Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. ( Gnad, U; Hartmann, JT; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Saussele, S; Weisser, A; Willer, A, 2004) |
| "Because of the poor response of pancreatic cancer to conventional therapy, the authors performed a phase II pilot study to evaluate whether beta-interferon and retinoids, added to active chemotherapeutic agents, could increase response rate and survival in a group of patients who had metastatic disease." | 2.69 | Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. ( Casucci, D; Frati, L; Gulino, A; Rea, S; Recchia, F; Sica, G, 1998) |
| "Patterns of failure reveal that pancreatic cancer involves three compartments: the pancreatic bed and regional lymph nodes, the liver and the peritoneal surfaces." | 2.68 | Regional chemotherapy for inoperable pancreatic carcinoma. ( George, WJ; Muchmore, JH; Preslan, JE, 1996) |
| "Most pancreatic cancers cannot be resected at the time of diagnosis." | 2.67 | [Chemotherapy of cancer of the exocrine pancreas]. ( Bonneterre, J, 1990) |
| "Preoperative chemoradiation for cancer of the pancreas and duodenal region was relatively well-tolerated and enhanced resectability and downstaging of nodal metastases were suggested." | 2.67 | Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. ( Coia, L; Eisenberg, B; Hanks, G; Hoffman, J; Paul, A; Scher, R; Solin, L; Weese, J; Weiner, L, 1994) |
| " Despite its pharmacokinetic advantages, the aortic stop flow technique is currently not recommendable for routine use." | 2.43 | Pharmacokinetics of the antineoplastic drug mitomycin C in regional chemotherapy using the aortic stop flow technique in advanced pancreatic carcinoma. ( Gebauer, T; Grote, R; Lippert, H; Martens-Lobenhoffer, J; Meyer, F; Ridwelski, K, 2005) |
| "Patients with pancreatic cancer are treated with combined treatment modalities." | 2.42 | [The update on pancreatic cancer chemotherapy]. ( Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E, 2003) |
| "It is well-known that the patients with pancreatic cancer are vulnerable for recurrence such as local relapse and liver metastasis after surgical resection." | 2.40 | [Therapeutic strategy for the recurrence of pancreatic cancer following pancreatectomy]. ( Egawa, S; Kobari, M; Matsuno, S; Shibuya, K; Shimamura, H; Sunamura, M; Takeda, K, 1999) |
| "For Dukes' C colon cancer, postoperative adjuvant chemotherapy with a combination of fluorouracil and levamisole is now recommended as standard therapy." | 2.39 | Adjuvant postoperative therapy of gastrointestinal malignancies. ( Ilson, DH; Kelsen, DP, 1994) |
| "In advanced pancreatic cancer, chemotherapy has no curative potential, and the goal is to palliate symptoms or delay their onset so as to improve the quality of life of patients." | 2.38 | [Chemotherapy for advanced pancreatic carcinoma]. ( Shimada, Y; Yokoyama, T, 1992) |
| "The effectiveness of MMC against human stomach cancers xenografted to nude mice clearly correlated to the clinical effect of MMC against gastric cancer." | 2.37 | [Recent advanced studies on mitomycins, antitumor activity and mode of action]. ( Morimoto, M; Taguchi, T, 1987) |
| "Gemcitabine and cisplatin were each capable of activating MK2, and we did not observe differences in the intracellular localization of MK2 upon treatment." | 1.48 | Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin. ( Dobbelstein, M; Köpper, F; Li, Y, 2018) |
| "Olaparib had substantial toxicity when combined with IC or ICM in patients with PDAC, and this treatment combination did not have an acceptable risk/benefit profile for further study." | 1.46 | Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. ( Azad, NS; De Jesus-Acosta, A; Donehower, RC; Fine, RL; Goggins, M; Jaffee, EM; Johnson, BA; Laheru, DA; Le, DT; Myzak, MC; Oberstein, PE; Yarchoan, M; Zheng, L, 2017) |
| "Thrombocytopenia was the most frequently observed grade 4 toxicity in both groups (11% after FM versus 12% after GC)." | 1.37 | Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. ( Brunner, TB; Fietkau, R; Sauer, R, 2011) |
| "We retrospectively assessed the benefits of 5-fluorouracil (5-FU)- and heparin-based portal infusion chemotherapy combined with systemic administration of mitomycin C (MMC) and cisplatin (CDDP) for 4 weeks following surgery (PI4W)." | 1.36 | Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer. ( Aiura, K; Kitagawa, Y; Matsui, J; Takahashi, S; Ueda, M, 2010) |
| "Nonfunctioning islet cell tumor of the pancreas is frequently found in young female." | 1.34 | [Management of nonfunctioning islet cell tumors of the pancreas]. ( Ding, XW; Hao, XS; Liang, H; Pan, Y; Wang, BG; Wang, XN, 2007) |
| "Two retrovirally complemented pancreatic cancer cell lines having defects in the Fanconi anemia pathway, PL11 (FANCC-mutated) and Hs766T (FANCG-mutated), as well as several parental pancreatic cancer cell lines with or without mutations in the Fanconi anemia/BRCA2 pathway, were assayed for in vitro and in vivo sensitivities to various chemotherapeutic agents." | 1.33 | In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. ( Brody, JR; Cunningham, SC; DeMarzo, AM; Dezentje, DA; Gallmeier, E; Hruban, RH; Isacoff, WH; Kern, SE; Offerhaus, GJ; Swartz, MJ; van der Heijden, MS, 2005) |
| "A patient with liver metastasis of pancreatic cancer received chemotherapy using mitomycin C and degradable starch microspheres." | 1.32 | Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres. ( Aoki, T; Kato, F; Katsumata, K; Koyanagi, Y; Sumi, T; Suzuki, Y; Takagi, M; Tomioka, H; Yamasaki, T, 2003) |
| "The use of neoadjuvant chemotherapy for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors, especially for patients with Stage IV b (Japan criteria)." | 1.32 | [Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics]. ( Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S, 2004) |
| "In patients with pancreatic cancer, the overall response rate was 42% with a median survival of 8 months." | 1.31 | Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. ( Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P, 2002) |
| "Our experience of arterial infusion chemotherapy combined with regional hyperthermia in the treatment of non-resectable pancreatic cancer was presented." | 1.31 | [Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival]. ( Endo, Y; Ikeda, H; Matumoto, Y; Miura, T, 2000) |
| "With gastric cancer, however, there was no significant difference." | 1.31 | [Hepatic arterial infusion chemotherapy for unresectable liver metastasis of gastrointestinal cancers]. ( Hirakawa, K; Nishino, H; Ohira, M; Shimizu, S; Tamamori, Y; Tanaka, H; Yamada, N, 2000) |
| "Gemcitabine treatment appeared most effective." | 1.31 | [Experience with chemotherapy for advanced pancreatic carcinoma]. ( Gershanovich, ML; Ignashov, AM; Ivanova, NE; Kokhanenko, NIu; Osipenko, SK; Rybakov, GV, 2000) |
| "We treated a case of unresectable gastric cancer in which peritoneal lavage cytology and the primary tumor responded to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection." | 1.31 | [A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection]. ( Hattori, T; Hirano, K; Kase, H; Kobayashi, K; Ogawa, M; Teramoto, T; Tokura, N; Washizawa, N, 2000) |
| " Compared with the cell necrosis, the dosage of drugs was less and the time was shorter for inducing apoptosis." | 1.30 | [Apoptosis of human pancreatic carcinoma cell lines induced by combinations of chemotherapeutic drugs]. ( Cai, L; Liao, Q; Wu, Y; Zhao, Y; Zhu, Y, 1999) |
| "In a patient with advanced pancreatic cancer, with a hypercoagulable state, a complete clinical response was obtained with a mitomycin-based regimen plus adjunctive heparin." | 1.30 | Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C-based chemotherapy: the role of adjunctive heparin. ( Latino, F; Sadoff, L, 1999) |
| "Chemotherapy for pancreatic cancer does not satisfactorily improve prognosis." | 1.29 | In vitro chemosensitivity of human pancreatic cancer cell lines. ( Oka, T; Sawabe, Y; Yamagishi, H; Yamaguchi, N; Yamamura, Y, 1996) |
| "A case of unresectable pancreatic cancer in a 76-year-old female was reported, in which a tumor had liver involvement." | 1.29 | [A case of pancreatic cancer surviving for 7 years 11 months following intra-arterial and portal infusion chemotherapy]. ( Endo, T; Ichikawa, J; Ishii, H; Kenmotsu, M; Tsunemitsu, K, 1995) |
| "Pancreatic cancer is a disease with essentially no effective treatment." | 1.29 | A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Watanabe, M, 1993) |
| "The current treatment of pancreatic cancer with resection and/or radiation is considered unsatisfactory because of a high incidence of failure and a moderate incidence of complications." | 1.28 | Isolated perfusion of pancreas with mitomycin C. ( Arredondo, MA; Chaudhuri, B; Chaudhuri, PK; Crist, KA; Kar, R; Thomford, NR, 1990) |
| "Nineteen patients with resectable pancreatic cancer have been treated by a multidisciplinary approach at the National Cancer Center Hospital." | 1.28 | Evidence of effective multidisciplinary treatment for resectable pancreatic cancer from the viewpoint of the CA19-9 level. ( Egawa, S; Kinoshita, T; Kosuge, T; Ozaki, H; Shimada, K; Yamamoto, J, 1991) |
| "These consisted of four gastric cancers (H-55, H-111, H-81 and H-154), one breast cancer (H-31) and one pancreatic cancer (H-48)." | 1.28 | [Combination chemotherapy of HO-221, a derivative of benzoylphenylurea with various anticancer agents against human cancer xenografts in nude mice]. ( Fujita, F; Fujita, M; Inaba, H; Okuyama, Y; Sugimoto, T; Taguchi, T, 1991) |
| "Four patients with unresectable pancreatic cancer and one with metastatic liver tumor after curative pancreatic resection for carcinoma of the pancreas had undergone intra-arterial infusion chemotherapy using an implantable drug delivery system." | 1.28 | [Long-term arterial infusion chemotherapy in unresectable pancreatic cancer]. ( Asamura, M; Kakizaki, K; Kikuti, H; Takahashi, N; Yamauchi, H, 1989) |
| " The portal concentration of MMC increased rapidly to the maximum concentration of 826 +/- 364 ng/ml at 5 minutes after administration, when the dosage was 20 mg (four cases)." | 1.28 | [Portal blood levels of mitomycin C after intraperitoneal administration]. ( Kakizaki, K; Yamada, Y; Yamauchi, H, 1992) |
| "Fourty eight patients with cancer of head of pancreas have been treated by the intra-arterial infusion of 5-FU and Mitomycin C alone or in combination with regional hyperthermia, employing microwave machine operating at a frequency of 2450 MHz." | 1.27 | [Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas]. ( Endo, Y; Funatomi, H; Hatta, Y; Hirose, N; Miura, T; Sassa, T; Taguchi, S; Yoshikawa, N, 1985) |
| "A woman with pancreatic cancer developed acute interstitial infiltrates while receiving modest doses of two potential pulmonary toxins, mitomycin-C and chlorozotocin." | 1.27 | Combination chemotherapy pneumonitis: a case report of possible synergistic toxicity. ( Goedert, JJ; Smith, FP; Tsou, E; Weiss, RB, 1983) |
| "The sensitivity of two human pancreatic adenocarcinomas (Capan-1 and Capan-2) to heat and heat combined with chemotherapy was studied using xenografts of the tumors in the foot of athymic nude mice." | 1.27 | Sensitivity of xenografts of human pancreatic adenocarcinoma in nude mice to heat and heat combined with chemotherapy. ( Cahan, A; Fogh, J; Fortner, JG; Shiu, MH, 1983) |
| "The incidence of pancreatic cancer has been increasing in recent years." | 1.27 | [Chemotherapy of pancreatic cancer]. ( Nakamura, K; Ozaki, H; Tajiri, H; Yoshimori, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 63 (31.66) | 18.7374 |
| 1990's | 61 (30.65) | 18.2507 |
| 2000's | 54 (27.14) | 29.6817 |
| 2010's | 20 (10.05) | 24.3611 |
| 2020's | 1 (0.50) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, Y | 3 |
| Kitago, M | 1 |
| Aiura, K | 2 |
| Shinoda, M | 1 |
| Yagi, H | 1 |
| Abe, Y | 1 |
| Oshima, G | 1 |
| Hori, S | 1 |
| Nakano, Y | 1 |
| Itano, O | 1 |
| Fukada, J | 1 |
| Masugi, Y | 1 |
| Kitagawa, Y | 2 |
| Yarchoan, M | 1 |
| Myzak, MC | 1 |
| Johnson, BA | 1 |
| De Jesus-Acosta, A | 2 |
| Le, DT | 1 |
| Jaffee, EM | 2 |
| Azad, NS | 1 |
| Donehower, RC | 2 |
| Zheng, L | 1 |
| Oberstein, PE | 1 |
| Fine, RL | 1 |
| Laheru, DA | 1 |
| Goggins, M | 1 |
| Li, Y | 1 |
| Köpper, F | 1 |
| Dobbelstein, M | 1 |
| Farshid, P | 1 |
| Darvishi, A | 1 |
| Naguib, N | 1 |
| Bazrafshan, B | 1 |
| Paul, J | 1 |
| Mbalisike, E | 1 |
| Vogl, TJ | 3 |
| Mezencev, R | 1 |
| Wang, L | 1 |
| Xu, W | 1 |
| Kim, B | 1 |
| Sulchek, TA | 1 |
| Daneker, GW | 1 |
| McDonald, JF | 1 |
| Drudi, F | 1 |
| Tassinari, D | 1 |
| Giuliani, J | 1 |
| Ridolfi, C | 1 |
| Gianni, L | 1 |
| Tamburini, E | 1 |
| Fantini, M | 1 |
| Santelmo, C | 1 |
| Barzotti, E | 1 |
| Lotti, N | 1 |
| Ravaioli, A | 1 |
| Heinrich, S | 4 |
| Kraft, D | 1 |
| Staib-Sebler, E | 4 |
| Schwarz, W | 2 |
| Gog, C | 4 |
| Vogl, T | 1 |
| Lorenz, M | 4 |
| Vyas, O | 1 |
| Leung, K | 1 |
| Ledbetter, L | 1 |
| Kaley, K | 1 |
| Rodriguez, T | 1 |
| Garcon, MC | 1 |
| Saif, MW | 2 |
| Yoshioka, M | 1 |
| Shibata, S | 1 |
| Uchinami, H | 1 |
| Watanabe, G | 3 |
| Miyazawa, H | 1 |
| Iida, M | 1 |
| Yoshida, M | 1 |
| Yoshioka, T | 1 |
| Nanjo, H | 1 |
| Yamamoto, Y | 1 |
| Lal, S | 1 |
| Zarei, M | 1 |
| Chand, SN | 1 |
| Dylgjeri, E | 1 |
| Mambelli-Lisboa, NC | 1 |
| Pishvaian, MJ | 1 |
| Yeo, CJ | 2 |
| Winter, JM | 1 |
| Brody, JR | 4 |
| Nakchbandi, W | 2 |
| Müller, H | 2 |
| Singer, MV | 2 |
| Lohr, JM | 1 |
| Nakchbandi, IA | 2 |
| Jin, C | 1 |
| Yao, L | 1 |
| Long, J | 1 |
| Fu, DL | 1 |
| Yu, XJ | 1 |
| Xu, J | 1 |
| Yang, F | 1 |
| Ni, QX | 1 |
| Dezentje, DA | 3 |
| Arking, DE | 1 |
| Kortenhorst, MS | 1 |
| West, K | 1 |
| Chakravarti, A | 1 |
| Kern, SE | 4 |
| Yoshizawa, J | 1 |
| Takizawa, A | 1 |
| Takeuchi, O | 1 |
| Hiraku, O | 1 |
| Sasaki, K | 1 |
| Morimoto, Y | 1 |
| Atsuda, K | 1 |
| Inoue, G | 1 |
| Suzuki, Y | 2 |
| Asanuma, F | 1 |
| Yamada, Y | 4 |
| Lee, S | 1 |
| Oh, SY | 1 |
| Kim, BG | 1 |
| Kwon, HC | 1 |
| Kim, SH | 1 |
| Rho, MH | 1 |
| Kim, YH | 1 |
| Rho, MS | 1 |
| Jeong, JS | 1 |
| Kim, HJ | 1 |
| Kruth, J | 1 |
| Nissen, J | 1 |
| Ernst, T | 1 |
| Kripp, M | 1 |
| Lukan, N | 1 |
| Merx, K | 1 |
| Hofmann, WK | 1 |
| Hochhaus, A | 2 |
| Hofheinz, RD | 2 |
| Dai, T | 1 |
| Takahashi, S | 1 |
| Matsui, J | 1 |
| Ueda, M | 1 |
| Lowery, M | 1 |
| Shah, MA | 1 |
| Smyth, E | 1 |
| Epstein, A | 1 |
| Segal, A | 1 |
| Rosengarten, O | 1 |
| Isacson, R | 1 |
| Drukker, L | 1 |
| Keinan, A | 1 |
| Rachkiman, M | 1 |
| Reissman, P | 1 |
| Gabizon, A | 2 |
| Kelsen, D | 1 |
| O'Reilly, EM | 1 |
| Villarroel, MC | 1 |
| Rajeshkumar, NV | 1 |
| Garrido-Laguna, I | 1 |
| Jones, S | 1 |
| Maitra, A | 1 |
| Hruban, RH | 4 |
| Eshleman, JR | 1 |
| Klein, A | 1 |
| Laheru, D | 1 |
| Donehower, R | 1 |
| Hidalgo, M | 1 |
| Lim, KH | 1 |
| Kim, TY | 2 |
| Lee, KH | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Bang, YJ | 1 |
| Cereda, S | 1 |
| Reni, M | 2 |
| Rognone, A | 1 |
| Fugazza, C | 1 |
| Ghidini, M | 1 |
| Ceraulo, D | 1 |
| Brioschi, M | 1 |
| Nicoletti, R | 2 |
| Villa, E | 2 |
| Brunner, TB | 1 |
| Sauer, R | 2 |
| Fietkau, R | 2 |
| Amitay, Y | 1 |
| Tzemach, D | 1 |
| Gorin, J | 1 |
| Shmeeda, H | 1 |
| Zalipsky, S | 1 |
| Cui, S | 1 |
| Ba, M | 1 |
| Tang, Y | 1 |
| Liu, J | 1 |
| Wu, Y | 2 |
| Wang, B | 1 |
| Zhang, X | 1 |
| Tang, H | 1 |
| Zhong, S | 1 |
| Maisey, N | 1 |
| Chau, I | 1 |
| Cunningham, D | 2 |
| Norman, A | 2 |
| Seymour, M | 1 |
| Hickish, T | 1 |
| Iveson, T | 1 |
| O'Brien, M | 1 |
| Tebbutt, N | 1 |
| Harrington, A | 1 |
| Hill, M | 2 |
| Slater, S | 1 |
| Shamash, J | 1 |
| Wilson, P | 1 |
| Gallagher, CJ | 1 |
| Slevin, ML | 1 |
| Liao, Q | 2 |
| Zhao, Y | 2 |
| Cai, L | 1 |
| Zhu, Y | 1 |
| Ji, Z | 1 |
| Wang, Y | 1 |
| Chen, X | 1 |
| Wu, T | 1 |
| Katsumata, K | 1 |
| Tomioka, H | 1 |
| Sumi, T | 1 |
| Yamasaki, T | 1 |
| Takagi, M | 1 |
| Kato, F | 1 |
| Aoki, T | 2 |
| Koyanagi, Y | 1 |
| Heller, M | 2 |
| Zangos, S | 2 |
| Eichler, K | 1 |
| Mack, MG | 1 |
| Berger, D | 1 |
| Balzer, JO | 1 |
| Kelleher, M | 1 |
| Tebbutt, NC | 1 |
| Andreyev, J | 1 |
| Allen, M | 1 |
| LANGDON, EA | 1 |
| OTTOMAN, RE | 1 |
| ROCHLIN, DB | 1 |
| SMART, CR | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| SULLIVAN, RD | 1 |
| ZUREK, WZ | 1 |
| Brasiūniene, B | 1 |
| Juozaityte, E | 1 |
| Brasiūnas, V | 1 |
| Inciūra, A | 1 |
| Varrassi, G | 1 |
| Guadagni, S | 3 |
| Ciccozzi, A | 1 |
| Marinangeli, F | 1 |
| Pozone, T | 1 |
| Piroli, A | 1 |
| Marsili, I | 1 |
| Paladini, A | 1 |
| Van Der Heijden, MS | 3 |
| Willer, A | 1 |
| Weisser, A | 1 |
| Gnad, U | 1 |
| Saussele, S | 1 |
| Kreil, S | 1 |
| Hartmann, JT | 1 |
| Hehlmann, R | 1 |
| Tuinmann, G | 1 |
| Hegewisch-Becker, S | 1 |
| Zschaber, R | 1 |
| Kehr, A | 1 |
| Schulz, J | 1 |
| Hossfeld, DK | 1 |
| van IJken, MG | 2 |
| van Etten, B | 1 |
| Guetens, G | 1 |
| ten Hagen, TL | 1 |
| Jeekel, J | 2 |
| de Bruijn, EA | 1 |
| Eggermont, AM | 2 |
| van Eijck, CH | 2 |
| Gallmeier, E | 2 |
| Cunningham, SC | 2 |
| Shen, D | 1 |
| Sasson, AR | 1 |
| Wetherington, RW | 1 |
| Hoffman, JP | 3 |
| Ross, EA | 1 |
| Cooper, H | 1 |
| Meropol, NJ | 1 |
| Freedman, G | 1 |
| Pingpank, JF | 1 |
| Eisenberg, BL | 3 |
| Taoka, H | 1 |
| Hirano, H | 1 |
| Mitsui, Y | 1 |
| Umino, W | 1 |
| Nobuoka, Y | 1 |
| Yamashita, M | 1 |
| Tanigawa, K | 1 |
| Yoshimine, S | 1 |
| Imai, T | 1 |
| Kadowaki, S | 1 |
| Miyashita, K | 1 |
| Ikuma, H | 1 |
| Nakamura, T | 1 |
| Murata, T | 1 |
| Panucci, MG | 1 |
| Passoni, P | 1 |
| Bonetto, E | 1 |
| Ronzoni, M | 1 |
| Zerbi, A | 1 |
| Staudacher, C | 1 |
| Di Carlo, V | 1 |
| Meyer, F | 1 |
| Ridwelski, K | 1 |
| Gebauer, T | 1 |
| Grote, R | 1 |
| Martens-Lobenhoffer, J | 1 |
| Lippert, H | 1 |
| Mizuta, Y | 1 |
| Akazawa, Y | 1 |
| Shiozawa, K | 1 |
| Ohara, H | 1 |
| Ohba, K | 1 |
| Ohnita, K | 1 |
| Isomoto, H | 1 |
| Takeshima, F | 1 |
| Omagari, K | 1 |
| Tanaka, K | 1 |
| Yasutake, T | 1 |
| Nakagoe, T | 1 |
| Shirono, K | 1 |
| Kohno, S | 1 |
| Cohen, SJ | 1 |
| Dobelbower, R | 1 |
| Lipsitz, S | 1 |
| Catalano, PJ | 1 |
| Sischy, B | 1 |
| Smith, TJ | 1 |
| Haller, DG | 1 |
| Bosch, X | 1 |
| Swartz, MJ | 1 |
| DeMarzo, AM | 1 |
| Offerhaus, GJ | 1 |
| Isacoff, WH | 2 |
| Han, GH | 1 |
| Yin, ZX | 1 |
| Meng, XJ | 1 |
| He, CY | 1 |
| Zhang, HB | 1 |
| Sun, AH | 1 |
| Wu, KC | 1 |
| Ding, J | 1 |
| Fan, DM | 1 |
| Miyazaki, S | 1 |
| Izukura, M | 1 |
| Nisijima, J | 1 |
| Mitchell, J | 1 |
| Keung, YK | 1 |
| Löhr, M | 1 |
| Suga, H | 1 |
| Okabe, Y | 1 |
| Ono, N | 1 |
| Saito, F | 1 |
| Nagaoka, S | 1 |
| Tsuruta, O | 1 |
| Toyonaga, A | 1 |
| Sata, M | 1 |
| Clementi, M | 1 |
| Valenti, M | 1 |
| Fiorentini, G | 1 |
| Cantore, M | 1 |
| Kanavos, E | 1 |
| Caterino, GP | 1 |
| Di Giuro, G | 1 |
| Amicucci, G | 1 |
| Bendetti, JK | 1 |
| Barstis, JJ | 1 |
| Jazieh, AR | 1 |
| Macdonald, JS | 2 |
| Philip, PA | 1 |
| Kolb-van Harten, P | 1 |
| Rosien, U | 1 |
| Klöppel, G | 1 |
| Layer, P | 1 |
| Hammerstingl, RM | 1 |
| Böcher, E | 1 |
| Jacob, U | 1 |
| Bauer, RW | 1 |
| Liang, H | 1 |
| Wang, XN | 1 |
| Wang, BG | 1 |
| Pan, Y | 1 |
| Ding, XW | 1 |
| Hao, XS | 1 |
| Edwards, SL | 1 |
| Brough, R | 1 |
| Lord, CJ | 1 |
| Natrajan, R | 1 |
| Vatcheva, R | 1 |
| Levine, DA | 1 |
| Boyd, J | 1 |
| Reis-Filho, JS | 1 |
| Ashworth, A | 1 |
| Chalasani, P | 1 |
| Kurtin, S | 1 |
| Dragovich, T | 1 |
| Steffensrud, S | 1 |
| Erichsen, H | 1 |
| Røysland, P | 1 |
| Halvorsen, TB | 1 |
| Klepp, R | 1 |
| Klepp, O | 1 |
| Wünsch, E | 1 |
| Petersen, H | 1 |
| Miura, T | 3 |
| Haida, K | 1 |
| Haida, S | 1 |
| Wada, T | 2 |
| Bukowski, RM | 5 |
| Schacter, LP | 1 |
| Groppe, CW | 1 |
| Hewlett, JS | 2 |
| Weick, JK | 2 |
| Livingston, RB | 2 |
| Gahbauer, R | 1 |
| Rodriquez-Antunez, A | 1 |
| Hermann, R | 1 |
| Theodors, A | 1 |
| Goedert, JJ | 1 |
| Smith, FP | 2 |
| Tsou, E | 1 |
| Weiss, RB | 1 |
| Manabe, T | 2 |
| Suzuki, T | 2 |
| Balcerzak, SP | 1 |
| O'Bryan, RM | 1 |
| Bonnet, JD | 1 |
| Chen, TT | 1 |
| Sternberg, CN | 1 |
| Magill, GB | 1 |
| Sordillo, PP | 1 |
| Cheng, EW | 1 |
| Bruckner, HW | 2 |
| Storch, JA | 1 |
| Brown, JC | 1 |
| Goldberg, J | 1 |
| Chamberlin, K | 1 |
| Shiu, MH | 1 |
| Cahan, A | 1 |
| Fogh, J | 1 |
| Fortner, JG | 1 |
| Wakui, A | 1 |
| Taguchi, T | 5 |
| Tajiri, H | 2 |
| Kitahara, T | 1 |
| Yoshimori, M | 2 |
| Nakamura, K | 2 |
| Hijikata, A | 1 |
| Ozaki, H | 6 |
| Sato, M | 2 |
| Ishidoya, T | 1 |
| Joko, Y | 1 |
| Kiyasu, Y | 1 |
| Sakai, K | 1 |
| Kimura, S | 1 |
| Harvey, JH | 1 |
| Schein, PS | 3 |
| Meguro, S | 1 |
| Nagata, T | 1 |
| Yokoyama, K | 1 |
| Chinen, T | 1 |
| Yamazaki, H | 1 |
| Kobayashi, T | 1 |
| Isogai, Y | 1 |
| Ogawa, M | 2 |
| Stablein, D | 1 |
| Korsmeyer, S | 1 |
| Neefe, J | 1 |
| Chun, BK | 1 |
| Woolley, PV | 1 |
| Agnelli, G | 1 |
| Gresele, P | 1 |
| Nenci, GG | 1 |
| Reich, SD | 1 |
| Chang, BK | 1 |
| Gutman, R | 1 |
| Kinami, Y | 2 |
| Konishi, K | 1 |
| Shinmura, K | 1 |
| Takada, M | 1 |
| Sakuma, H | 1 |
| Nagakawa, T | 2 |
| Miyazaki, I | 2 |
| Kenmotsu, M | 1 |
| Endo, T | 1 |
| Ishii, H | 1 |
| Ichikawa, J | 1 |
| Tsunemitsu, K | 1 |
| Nishiyama, M | 3 |
| Saeki, S | 2 |
| Aogi, K | 2 |
| Hirabayashi, N | 3 |
| Toge, T | 3 |
| Weese, JL | 2 |
| Solin, LJ | 2 |
| Agarwal, P | 1 |
| Engstrom, P | 1 |
| Scher, R | 2 |
| Paul, AR | 3 |
| Litwin, S | 2 |
| Watts, P | 1 |
| Ilson, DH | 1 |
| Kelsen, DP | 1 |
| Palmer, KR | 1 |
| Kerr, M | 1 |
| Knowles, G | 1 |
| Cull, A | 1 |
| Carter, DC | 1 |
| Leonard, RC | 1 |
| Kato, H | 4 |
| Wakasugi, H | 1 |
| Yokota, M | 1 |
| Furukawa, M | 1 |
| Mukuta, T | 1 |
| Funakoshi, A | 1 |
| Coia, L | 1 |
| Hoffman, J | 1 |
| Weese, J | 1 |
| Solin, L | 1 |
| Weiner, L | 1 |
| Eisenberg, B | 1 |
| Paul, A | 1 |
| Hanks, G | 1 |
| Gotoh, M | 2 |
| Monden, M | 2 |
| Sakon, M | 2 |
| Kanai, T | 1 |
| Umeshita, K | 2 |
| Ikeda, H | 2 |
| Mori, T | 1 |
| Furukawa, T | 1 |
| Kubota, T | 1 |
| Watanabe, M | 1 |
| Kitajima, M | 1 |
| Hoffman, RM | 1 |
| Satou, T | 1 |
| Yeung, RS | 1 |
| Engstrom, PF | 2 |
| Kowalyshyn, MJ | 1 |
| Fleming, TR | 2 |
| Oishi, N | 1 |
| Taylor, SA | 1 |
| Baker, LH | 1 |
| Bakkevold, KE | 1 |
| Arnesjø, B | 1 |
| Dahl, O | 1 |
| Kambestad, B | 1 |
| Topham, C | 2 |
| Glees, J | 2 |
| Coombes, RC | 2 |
| Lai, DT | 1 |
| Chu, KM | 1 |
| Thompson, JF | 1 |
| Gallagher, JP | 1 |
| Waugh, R | 1 |
| Storey, DW | 1 |
| Stephen, MS | 1 |
| Kinoshita, T | 4 |
| Kosuge, T | 4 |
| Yamamoto, J | 3 |
| Shimada, K | 3 |
| Inoue, K | 1 |
| Koyama, Y | 1 |
| Mukai, K | 2 |
| Takada, T | 2 |
| Matsushiro, T | 2 |
| Nimura, Y | 2 |
| Nakayama, T | 1 |
| Yamauchi, H | 6 |
| Ogata, Y | 1 |
| Shimada, H | 1 |
| Miyakawa, S | 1 |
| Yamaguchi, A | 1 |
| Sakoda, K | 1 |
| Yasuda, H | 1 |
| Tsukada, K | 1 |
| Yoshida, K | 2 |
| Ashida, H | 1 |
| Ishikawa, Y | 1 |
| Kotoura, Y | 1 |
| Kinoshita, H | 1 |
| Kajiwara, T | 1 |
| Uchimura, M | 1 |
| Funabiki, T | 1 |
| Ikeda, S | 1 |
| Okada, S | 2 |
| Muchmore, JH | 1 |
| Preslan, JE | 1 |
| George, WJ | 1 |
| Weckbecker, G | 1 |
| Raulf, F | 1 |
| Tolcsvai, L | 1 |
| Bruns, C | 1 |
| Osato, H | 1 |
| Kishimoto, S | 1 |
| Yamada, T | 1 |
| Higaki, N | 1 |
| Taniguchi, K | 1 |
| Sugimoto, K | 1 |
| Dohno, K | 1 |
| Sawabe, Y | 1 |
| Yamagishi, H | 1 |
| Yamaguchi, N | 1 |
| Yamamura, Y | 1 |
| Oka, T | 1 |
| Yamaguchi, T | 2 |
| Yamaoka, N | 1 |
| Kitamura, K | 2 |
| Otsuji, E | 2 |
| Okamoto, K | 2 |
| Tsuruta, H | 1 |
| Yata, Y | 1 |
| Takahashi, T | 2 |
| Recchia, F | 1 |
| Sica, G | 1 |
| Casucci, D | 1 |
| Rea, S | 1 |
| Gulino, A | 1 |
| Frati, L | 1 |
| Blaszkowsky, L | 1 |
| Petrowsky, H | 3 |
| Janshon, G | 3 |
| Poloczek, Y | 2 |
| Oremek, G | 2 |
| Encke, A | 1 |
| Patiutko, IuI | 1 |
| Kotel'nikov, AG | 1 |
| Badalian, KhV | 1 |
| Sagaĭdak, IV | 1 |
| Sadoff, L | 1 |
| Latino, F | 1 |
| Sunamura, M | 1 |
| Egawa, S | 3 |
| Shibuya, K | 1 |
| Shimamura, H | 1 |
| Takeda, K | 1 |
| Kobari, M | 2 |
| Matsuno, S | 2 |
| Xue, C | 1 |
| Minari, Y | 1 |
| Nio, Y | 2 |
| Endo, S | 1 |
| Yano, S | 1 |
| Itakura, M | 1 |
| Yamasawa, K | 1 |
| Tamura, K | 1 |
| Tokuuye, K | 1 |
| Fukushima, N | 2 |
| Kastl, S | 1 |
| Brunner, T | 1 |
| Herrmann, O | 1 |
| Riepl, M | 1 |
| Grabenbauer, G | 1 |
| Hohenberger, W | 1 |
| Klein, P | 1 |
| Burch, PA | 1 |
| Ghosh, C | 1 |
| Schroeder, G | 1 |
| Allmer, C | 1 |
| Woodhouse, CL | 1 |
| Goldberg, RM | 1 |
| Addo, F | 1 |
| Bernath, AM | 1 |
| Tschetter, LK | 2 |
| Windschitl, HE | 2 |
| Cobau, CD | 1 |
| Chakravarthy, A | 1 |
| Abrams, RA | 1 |
| Korman, LT | 1 |
| Zahurek, ML | 1 |
| Grochow, LB | 1 |
| O'Reilly, S | 1 |
| Hurwitz, H | 1 |
| Lillemoe, KD | 1 |
| Cameron, JL | 1 |
| Matumoto, Y | 1 |
| Tamamori, Y | 1 |
| Nishino, H | 1 |
| Yamada, N | 1 |
| Shimizu, S | 1 |
| Tanaka, H | 1 |
| Ohira, M | 1 |
| Hirakawa, K | 1 |
| Washizawa, N | 1 |
| Tokura, N | 1 |
| Kase, H | 1 |
| Hattori, T | 1 |
| Teramoto, T | 1 |
| Kobayashi, K | 1 |
| Hirano, K | 1 |
| Kornek, GV | 1 |
| Pötter, R | 1 |
| Selzer, E | 1 |
| Schratter, A | 1 |
| Ulrich-Pur, H | 1 |
| Rogy, M | 1 |
| Kraus, G | 1 |
| Scheithauer, W | 1 |
| Kokhanenko, NIu | 1 |
| Gershanovich, ML | 1 |
| Ignashov, AM | 1 |
| Osipenko, SK | 1 |
| Rybakov, GV | 1 |
| Ivanova, NE | 1 |
| Tanada, M | 1 |
| Takashima, S | 2 |
| Endoh, H | 1 |
| Hyoudou, I | 1 |
| Jinno, K | 1 |
| Kataoka, M | 1 |
| Ni, Q | 1 |
| Zhang, Q | 1 |
| Cao, G | 1 |
| Hofland, J | 1 |
| Tenbrinck, R | 1 |
| Erdmann, W | 1 |
| Homma, H | 1 |
| Niitsu, Y | 1 |
| Yachida, S | 1 |
| Sakamoto, M | 1 |
| Matsuno, Y | 1 |
| Hirohashi, S | 1 |
| Kakizaki, K | 4 |
| Yokoyama, T | 1 |
| Shimada, Y | 1 |
| Sasaki, M | 1 |
| Kajihara, T | 1 |
| Hanaue, H | 1 |
| Shimizu, T | 1 |
| Arinaga, S | 2 |
| Karimine, N | 1 |
| Takamuku, K | 1 |
| Nanbara, S | 1 |
| Inoue, H | 1 |
| Abe, R | 1 |
| Watanabe, D | 1 |
| Matsuoka, H | 1 |
| Ueo, H | 1 |
| Akiyoshi, T | 2 |
| Sugiyama, Y | 1 |
| Saji, S | 2 |
| Furuta, T | 2 |
| Azuma, S | 2 |
| Miya, K | 1 |
| Umemoto, T | 1 |
| Takao, H | 1 |
| Kato, M | 1 |
| Kanno, A | 1 |
| Kunimura, T | 1 |
| Morohoshi, T | 1 |
| Kikuchi, H | 1 |
| Kanda, M | 1 |
| Taguchi, S | 2 |
| Hatta, Y | 2 |
| Miura, K | 1 |
| Mohiuddin, M | 2 |
| Rosato, F | 1 |
| Barbot, D | 2 |
| Schuricht, A | 1 |
| Biermann, W | 2 |
| Cantor, R | 1 |
| Verhees, S | 1 |
| Flechtner, H | 1 |
| Queisser, W | 1 |
| Heim, ME | 1 |
| Fritz, M | 1 |
| Trux, F | 1 |
| Edler, L | 1 |
| Arredondo, MA | 1 |
| Chaudhuri, B | 1 |
| Kar, R | 1 |
| Crist, KA | 1 |
| Thomford, NR | 1 |
| Chaudhuri, PK | 1 |
| Sato, Y | 1 |
| Tohma, H | 1 |
| Shikama, T | 1 |
| Sakata, Y | 1 |
| Chiba, Y | 1 |
| Sato, T | 1 |
| Kimura, M | 1 |
| Fukushi, G | 1 |
| Matsukawa, M | 1 |
| Wada, K | 1 |
| Aoyama, H | 1 |
| Sawada, Y | 1 |
| Fukushi, M | 1 |
| Rawson, NS | 1 |
| Woods, EM | 1 |
| Fujita, F | 3 |
| Fujita, M | 3 |
| Inaba, H | 2 |
| Sugimoto, T | 1 |
| Okuyama, Y | 1 |
| Abad, A | 1 |
| Rosell, R | 1 |
| Barnadas, A | 1 |
| Carles, J | 1 |
| Ribelles, N | 1 |
| Solano, V | 1 |
| Imai, S | 1 |
| Shiraishi, T | 1 |
| Tsubono, M | 1 |
| Morimoto, H | 1 |
| Tseng, CC | 1 |
| Tobe, T | 2 |
| Yamada, H | 1 |
| Moriai, T | 3 |
| Takeba, T | 1 |
| Makino, I | 1 |
| Jinushi, K | 1 |
| Kirihara, Y | 1 |
| Takagami, S | 1 |
| Ryuji, K | 1 |
| Yorishima, T | 1 |
| Noso, Y | 1 |
| Hisano, H | 1 |
| Akaishi, S | 1 |
| Seydel, HG | 1 |
| Stablein, DM | 1 |
| Leichman, LP | 1 |
| Kinzie, JJ | 1 |
| Thomas, PR | 1 |
| Bonneterre, J | 1 |
| Noguchi, A | 1 |
| Honda, M | 1 |
| Cullinan, S | 1 |
| Moertel, CG | 2 |
| Wieand, HS | 1 |
| Schutt, AJ | 1 |
| Krook, JE | 2 |
| Foley, JF | 2 |
| Norris, BD | 1 |
| Kardinal, CG | 1 |
| Barlow, JF | 1 |
| Lipton, A | 1 |
| Harvey, HA | 1 |
| Santen, RJ | 1 |
| Stryker, JA | 1 |
| Barnes, SG | 1 |
| Walker, BK | 1 |
| Dixon, RH | 1 |
| Givant, EM | 1 |
| Bartholomew, MJ | 1 |
| Nadjafi, C | 1 |
| Sassa, T | 1 |
| Yoshikawa, N | 1 |
| Hirose, N | 1 |
| Funatomi, H | 1 |
| Hasegawa, H | 1 |
| Hayakawa, N | 1 |
| Kamiya, J | 1 |
| Maeda, S | 1 |
| Shionoya, S | 1 |
| Kunitomo, K | 1 |
| Kawahito, M | 1 |
| Miura, M | 1 |
| Komi, N | 1 |
| Vaughn, C | 1 |
| Chapman, J | 1 |
| Chinn, B | 1 |
| Ward, D | 1 |
| Groshko, G | 1 |
| Maniscalco, B | 1 |
| Reznik, S | 1 |
| Piper, D | 1 |
| Klapdor, R | 2 |
| Schwarzenberg, O | 1 |
| Kühl, JS | 1 |
| Franke, N | 2 |
| Bahlo, M | 2 |
| Takahashi, N | 1 |
| Kikuti, H | 1 |
| Asamura, M | 1 |
| Yasuda, T | 1 |
| Ishikawa, O | 1 |
| Ohigashi, H | 1 |
| Shibata, T | 1 |
| Sasaki, Y | 1 |
| Hiratsuka, M | 1 |
| Kabuto, T | 1 |
| Furukawa, H | 1 |
| Imaoka, S | 1 |
| Iwanaga, T | 1 |
| Kalman, J | 1 |
| Spigelman, M | 1 |
| Gorbaty, MI | 1 |
| Butwell, N | 1 |
| Storch, J | 1 |
| McKenna, A | 1 |
| Maruyama, T | 1 |
| Koura, Y | 1 |
| Kurisu, Y | 1 |
| Kuroi, K | 1 |
| Kai, Y | 1 |
| Cullinan, SA | 1 |
| Rubin, JR | 1 |
| Everson, LK | 1 |
| Twito, DI | 1 |
| Marschke, RF | 1 |
| Splinter, TA | 1 |
| Obertop, H | 1 |
| Kok, TC | 1 |
| Oster, MW | 1 |
| Gray, R | 1 |
| Panasci, L | 1 |
| Perry, MC | 1 |
| Yamauchi, T | 1 |
| Sakamoto, Y | 1 |
| Shimozuma, K | 2 |
| Kimoto, Y | 1 |
| Takebe, T | 1 |
| Ohyama, K | 1 |
| Koba, F | 1 |
| Tsuji, H | 1 |
| Takahashi, Y | 1 |
| Ohta, T | 1 |
| Mai, M | 1 |
| Morimoto, M | 1 |
| Follezou, JY | 1 |
| Baumelou, A | 1 |
| Audebert, A | 1 |
| Beaufils, H | 1 |
| Karkouche, B | 1 |
| Kusuyama, T | 1 |
| Origasa, H | 1 |
| Uchida, Y | 1 |
| Yamaoka, K | 1 |
| Kisu, T | 1 |
| Mori, H | 1 |
| Muto, Y | 1 |
| Cantor, RJ | 1 |
| Weiss, SM | 1 |
| Rosato, FE | 1 |
| Tanemura, H | 1 |
| Kawata, R | 1 |
| Suzuki, M | 1 |
| Shimokawa, K | 1 |
| Ohashi, H | 1 |
| Sakata, K | 1 |
| Hojo, K | 1 |
| Kishi, K | 1 |
| Omote, Y | 1 |
| Stachura, J | 1 |
| Popiela, T | 1 |
| Pietroń, M | 1 |
| Tomaszewska, R | 1 |
| Kulig, J | 1 |
| Nowak, K | 1 |
| Okawa, T | 1 |
| Kita, M | 1 |
| Weiner, LM | 1 |
| Steplewski, Z | 1 |
| Koprowski, H | 1 |
| Tanaka, T | 1 |
| Arizuka, S | 1 |
| Ashida, Y | 1 |
| Naitoh, A | 1 |
| Miyashita, T | 1 |
| Takahashi, M | 1 |
| Abe, M | 1 |
| Hanyu, F | 1 |
| Nakamura, M | 1 |
| Suda, Y | 1 |
| Sekine, T | 1 |
| Eckhardt, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Multi-center Phase I/II Trial of ICM (Irinotecan, Cisplatin, Mitomycin C) With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer[NCT01296763] | Phase 1 | 18 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Feasibility Study for Individualized Treatment of Patients With Advanced Pancreatic Cancer[NCT00276744] | Phase 2 | 249 participants (Actual) | Interventional | 2005-10-31 | Terminated (stopped due to Because there was no longer an active laboratory component to this study.) | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| A Prospective Randomized Trial of Regional Versus Systemic Continuous Gemcitabine Chemotherapy in the Treatment of Unresectable Pancreatic Cancer[NCT01665625] | 90 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | |||
| A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma[NCT00003018] | Phase 2 | 54 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"1.Phase I - Assess the safety and toxicities of IC with Olaparib escalating to ICM with Olaparib in patients with locally advanced and metastatic pancreatic cancer and determine the phase 2 dose. The number of subjects who experienced a dose limiting toxicity was assessed.Dose-limiting toxicity (DLT) is defined as any of the following study drug-related events experienced during Cycle 1:~Thrombocytopenia with platelets <25,000 x106/l > 7 days. Grade 4 neutropenia lasting ≥7 days. Grade 3 or 4 febrile neutropenia. Grade 3 or greater non-haematological toxicities; excluding grade 3 diarrhoea, nausea or vomiting despite adequate treatment and grade 3 fatigue, lethargy and GGT elevation.~Delay of >2 weeks for next scheduled IC/ICM for reasons of toxicity." (NCT01296763)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Dose Level 1 | 0 |
| Dose Level 2 | 2 |
| Dose Level 5 | 2 |
The overall survival of subjects with locally advanced and/or metastatic pancreatic cancer treated with Irinotecan, Cisplatin, Olaparib, with escalation to the addition of Mitomycin-C. Survival from cycle 1, day 1 on-study to date of death was assessed. (NCT01296763)
Timeframe: 5 years
| Intervention | years (survival) from C1D1 to death (Mean) |
|---|---|
| Dose Level 1 | 1.43 |
| Dose Level 2 | 0.44 |
| Dose Level 5 | 0.60 |
Percentage of patients survived at 6 months for patients whose tumors were xenografted and treated in the mouse when treated with the most active agent identified in that model (NCT00276744)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 | 53 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
17 reviews available for mitomycin and Cancer of Pancreas
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
[Radically resected pancreatic cancer and adjuvant treatment. A review of the literature].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
[The update on pancreatic cancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
Pharmacokinetics of the antineoplastic drug mitomycin C in regional chemotherapy using the aortic stop flow technique in advanced pancreatic carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Area Under Curve; Biological Availability; Chemotherapy, C | 2005 |
Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
[Significance of thermo-chemotherapy for the patients with unresectable pancreas cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; | 2006 |
[Arterial infusion chemotherapy for patients with advanced pancreatic cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug | 2006 |
Adjuvant postoperative therapy of gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1994 |
Treatment of advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis | 1998 |
[Ways of improving long-term results of treatment in resectable pancreatic cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy; Evaluation | 1998 |
[Therapeutic strategy for the recurrence of pancreatic cancer following pancreatectomy].
Topics: Infusions, Intra-Arterial; Liver Neoplasms; Mitomycin; Neoplasm Recurrence, Local; Pancreatectomy; P | 1999 |
[Radiotherapy and chemotherapy for unresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2002 |
[A new regional arterial infusion chemotherapy for patients with advanced pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Embolization, Therapeutic; Fluorouracil; | 2002 |
[Chemotherapy for advanced pancreatic carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclo | 1992 |
[Recent advanced studies on mitomycins, antitumor activity and mode of action].
Topics: Animals; Cell Line; Colonic Neoplasms; Humans; Leukemia P388; Mitomycin; Mitomycins; Neoplasms; Panc | 1987 |
The role of chemotherapy in the management of gastric and pancreatic carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
Potentiation of antimetabolite action by alkylating agents.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1985 |
57 trials available for mitomycin and Cancer of Pancreas
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Chemoembolization, Therapeutic; Colorect | 2013 |
Phase II study on combined intravenous and intra-arterial chemotherapy with gemcitabine and mitomycin C in patients with advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; In | 2013 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine | 2009 |
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Topics: Animals; Deoxycytidine; Disease Progression; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; | 2011 |
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant | 2011 |
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dis | 2011 |
B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Chemotherapy, Cancer, Regional Perfus | 2012 |
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2002 |
Peripancreatic artery ligation and artery infusion chemotherapy for advanced pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arteries; Female; Fluorouracil; Humans; Infusions, I | 2003 |
[Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2003 |
Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Fema | 2003 |
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Dox | 2004 |
Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycyti | 2004 |
Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for locally advanced pancreatic cancer: a phase I-II trial.
Topics: Aged; Antineoplastic Agents; Balloon Occlusion; Chemotherapy, Cancer, Regional Perfusion; Female; Hu | 2004 |
Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytoge | 2004 |
A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2005 |
Prospective randomized clinical trial of two drug delivery pathway in the treatment of inoperable advanced pancreatic carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2006 |
Hypoxic abdominal stop-flow perfusion in the treatment of advanced pancreatic cancer: a phase II evaluation/trial.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Drug Therapy, Comb | 2007 |
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipy | 2007 |
Treatment with secretin and a cholecystokinin-like peptide in patients with pancreatic cancer. A pilot study.
Topics: Adenocarcinoma; Aged; Alanine Transaminase; Alkaline Phosphatase; Amylases; Antineoplastic Combined | 1984 |
Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Therapy, | 1983 |
MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxo | 1984 |
Pharmaceutics: mitomycin C: a brief review.
Topics: Adenocarcinoma; Clinical Trials as Topic; Humans; Mitomycin; Mitomycins; Pancreatic Neoplasms; Stoma | 1982 |
Chemotherapy prolongs survival in inoperable pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Depression; | 1994 |
Effectiveness of chemotherapy for advanced adenocarcinoma of the pancreas in combined modality therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Autonomic Nerve Block; Celiac Plexus; Combined Modal | 1994 |
Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1994 |
Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Duodenal Neoplasms; | 1993 |
Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac | 1993 |
Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvan | 1993 |
Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Flu | 1993 |
[Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Doxorubicin; F | 1996 |
Regional chemotherapy for inoperable pancreatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Infusi | 1996 |
Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diterpenes; Epirubicin; | 1998 |
Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer.
Topics: Aged; Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Hypoxia | 1998 |
Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer.
Topics: Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Humans; Hypoxia; Mitomycin; N | 1999 |
Neoadjuvant radio-chemotherapy in advanced primarilynon-resectable carcinomas of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Radiation; Fluor | 2000 |
Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Female | 2000 |
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deo | 2001 |
Cardiovascular effects of simultaneous occlusion of the inferior vena cava and aorta in patients treated with hypoxic abdominal perfusion for chemotherapy.
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Chem | 2002 |
[Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, | 1992 |
[Treatment of advanced pancreatic cancer with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM II). From the Chemotherapy of Gastrointestinal Tumors Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Epirubicin; F | 1990 |
[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colorectal Neopla | 1990 |
[Comparative study of UFT plus mitomycin C and UFT plus doxorubicin in adenocarcinoma. Hirosaki Cooperative Group of Cancer Chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Proto | 1992 |
Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Fol | 1991 |
[Chemotherapy of cancer of the exocrine pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Infusions, Intra- | 1990 |
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Proto | 1990 |
FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic carcinoma.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxoru | 1990 |
Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Combined Chemother | 1989 |
A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Costs and | 1985 |
Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl | 1986 |
Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Admin | 1986 |
Combined modality treatment of localized unresectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Clinical Trials as To | 1988 |
Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1986 |
The role of chemotherapy in the management of gastric and pancreatic carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1985 |
127 other studies available for mitomycin and Cancer of Pancreas
| Article | Year |
|---|---|
Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cispla | 2017 |
Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Repl | 2018 |
Molecular analysis of the inhibitory effect of N-acetyl-L-cysteine on the proliferation and invasiveness of pancreatic cancer cells.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Sen | 2013 |
Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation.
Topics: Adenocarcinoma; Antineoplastic Agents; BRCA2 Protein; Enzyme Inhibitors; Female; Humans; Jews; Male; | 2015 |
The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Is | 2015 |
WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumo | 2016 |
Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional | 2008 |
Hybrids of aneuploid human cancer cells permit complementation of simple and complex cancer defects.
Topics: Aneuploidy; Cell Line, Tumor; Dose-Response Relationship, Drug; Fanconi Anemia Complementation Group | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Prolifer | 2009 |
Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma.
Topics: Aged; Antibiotics, Antineoplastic; Genes, BRCA2; Humans; Lung Diseases, Interstitial; Male; Mitomyci | 2010 |
Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2010 |
A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cisplatin; Deox | 2011 |
Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluor | 2011 |
Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Topics: Animals; Antibiotics, Antineoplastic; Cholesterol; Colonic Neoplasms; Drug Carriers; Drug Stability; | 2012 |
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2002 |
[Apoptosis of human pancreatic carcinoma cell lines induced by combinations of chemotherapeutic drugs].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Doxorubicin; Epirubicin; Flu | 1999 |
Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Diseases; Carcinoma, Hepatocellular; Chemo | 2003 |
EARLY RESULTS OF COMBINED RADIATION AND CHEMOTHERAPY IN TREATMENT OF MALIGNANT TUMORS.
Topics: Antineoplastic Agents; Colonic Neoplasms; Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Mitomy | 1963 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf | 1964 |
Hemodynamic variations during thoracic and abdominal stop-flow regional chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2004 |
Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Fanconi Anemia; Fanconi Anemia Complementation Group D2 | 2004 |
Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
Topics: Cell Cycle Proteins; Cisplatin; Cross-Linking Reagents; DNA Mutational Analysis; DNA-Binding Protein | 2004 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2003 |
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2004 |
Fluorouracil and mitomycin for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Mit | 2005 |
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle; Cell Line, Tumor; Ce | 2005 |
Acute myeloid leukemia following intraperitoneal hyperthermic mitomycin C.
Topics: Acute Disease; Adenocarcinoma; Adult; Chromosome Inversion; Chromosomes, Human, Pair 16; Female; Hum | 2006 |
Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma.
Topics: Antibiotics, Antineoplastic; Anticoagulants; Carcinoma; Deoxycytidine; Dose-Response Relationship, D | 2006 |
Pancreatic acinar cell carcinoma with excessive alpha-fetoprotein expression.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Acinar Cell; Deoxycytidine; Gemcitabine; | 2007 |
[Transarterial chemoperfusion with gemcitabine and mitomycin C in pancreatic carcinoma: results in locally recurrent tumors and advanced tumor stages].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Sche | 2007 |
[Management of nonfunctioning islet cell tumors of the pancreas].
Topics: Adenoma, Islet Cell; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2007 |
Resistance to therapy caused by intragenic deletion in BRCA2.
Topics: Aged; Alleles; Amino Acid Sequence; Base Sequence; BRCA2 Protein; Carboplatin; Cell Line, Tumor; Chr | 2008 |
Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Female; Genes, BRCA | 2008 |
Intraarterial infusion chemotherapy in combination with 2450-MHz microwave hyperthermia for cancer of the head of the pancreas.
Topics: Antibiotics, Antineoplastic; Bleomycin; Drug Therapy, Combination; Female; Hot Temperature; Humans; | 1982 |
Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Drug Therapy, Comb | 1982 |
Mixed beam radiotherapy and combination chemotherapy in localized pancreatic adenocarcinoma-preliminary results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Elementary Particles; | 1982 |
Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineop | 1982 |
Combination chemotherapy pneumonitis: a case report of possible synergistic toxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Synergism; Drug Therapy, Combination; Female; Huma | 1983 |
[Surgery and drug therapy of advanced pancreatic cancer].
Topics: Adult; Aged; Delayed-Action Preparations; Drug Therapy, Combination; Female; Fluorouracil; Humans; M | 1982 |
Phase II trial of combination chemotherapy for pancreatic cancer with 5-fluorouracil, mitomycin C, and hexamethylmelamine.
Topics: Altretamine; Antibiotics, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Drug Therap | 1983 |
Sensitivity of xenografts of human pancreatic adenocarcinoma in nude mice to heat and heat combined with chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Cisplatin; Fluorouracil; Hot Temperature; | 1983 |
[Analysis of factors affecting clinical cancer chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Fluorouraci | 1983 |
[An autopsy report of pancreatic carcinoma following the achievement of significant prolongation of survival, despite the lack of a definitive diagnosis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphatic Metastasis | 1984 |
[Constant intra-aortic infusion chemotherapy for advanced abdominal cancer--a technic and the effect in patients with peritoneal metastases].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Coloni | 1984 |
Chemotherapy of pancreatic carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; M | 1984 |
Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Humans; L | 1984 |
Combination chemotherapy for locally advanced pancreatic cancer: equivalence to external beam irradiation and implication for future management.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma | 1983 |
Clotting activation after blood transfusion in patients receiving 5-fluorouracil and mitomycin-C treatment.
Topics: Blood Coagulation; Blood Transfusion; Fluorouracil; Humans; Mitomycin; Mitomycins; Pancreatic Neopla | 1981 |
Chemotherapy of pancreatic adenocarcinoma: initial report on two transplantable models in the Syrian hamster.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cricetinae; Cyclophosphamide; Disease Models, Animal | 1982 |
[Effect of cancer chemotherapy for unresectable cancer of the pancreas].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver Neoplasms; Mal | 1982 |
[A case of pancreatic cancer surviving for 7 years 11 months following intra-arterial and portal infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Disease-Free Survival; Female; Humans; Infusions, Intra-Arterial; Infusions, I | 1995 |
[Mitomycin C and its bioreduction: relevance of NAD(P)H: quinone oxidoreductase activity to mitomycin C-induced DNA damage and cytotoxicity].
Topics: Carcinoma, Squamous Cell; Cell Division; Dicumarol; DNA Damage; Humans; Leukemia, Myeloid; Mitomycin | 1993 |
A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgi | 1993 |
[An appraisal of intraoperative radiotherapy for pancreas cancer].
Topics: Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Intraoperative Care; Male; Middle Aged; Mitomyc | 1993 |
A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice.
Topics: Animals; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopl | 1993 |
[Importance of systemic administration of pyrimidine after thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Gas | 1993 |
Islet cell carcinoma treated by induction regional chemotherapy and radical total pancreatectomy with liver revascularization and small bowel autotransplantation.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
An aggressive therapeutic approach to carcinoma of the body and tail of the pancreas.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Combined Modality Therapy; Duod | 1996 |
Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antine | 1996 |
[A patient with pancreatic acinar cell carcinoma, effectively treated by the infusion chemotherapy through hepatic artery using 5-FU, CDDP and MMC].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Cisplatin; Drug Administrati | 1996 |
In vitro chemosensitivity of human pancreatic cancer cell lines.
Topics: Aged; Antimetabolites; Antineoplastic Agents; Carcinoma, Ductal, Breast; Cisplatin; DNA Replication; | 1996 |
Changes in expression of the antigen recognized by monoclonal antibody A7 in human pancreatic carcinoma cells following exposure to anticancer agents.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antigens, Neoplasm; Carcinoma; Cell Count; Cell | 1998 |
[Isolated hypoxic perfusion with mitomycin C confers no benefit for patients with advanced pancreatic carcinoma].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Cell Hypoxia; Disease Progression; Female; Humans | 1998 |
Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C-based chemotherapy: the role of adjunctive heparin.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Drug Therapy, | 1999 |
[The effect of blood-pancreatic juice barrier on antitumor drugs excretion].
Topics: Ampulla of Vater; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Dogs; Fluor | 1997 |
[Technique and pathophysiology of isolated hypoxic perfusion of the abdomen].
Topics: Acid-Base Equilibrium; Aged; Antibiotics, Antineoplastic; Carbon Dioxide; Catheterization; Chemother | 1999 |
[A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2000 |
Long-term survival after multimodality treatment for resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Mitomycin; Pancr | 2000 |
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2000 |
[Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; | 2000 |
[Hepatic arterial infusion chemotherapy for unresectable liver metastasis of gastrointestinal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorouracil; Hepati | 2000 |
[A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 2000 |
[Experience with chemotherapy for advanced pancreatic carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; D | 2000 |
[Multimodal treatment including intraoperative irradiation for advanced pancreatic cancer with extended metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2001 |
["Three steps procedure" in the treatment of large pancreatic head cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholecystostomy; | 2000 |
Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2002 |
[Portal blood levels of mitomycin C after intraperitoneal administration].
Topics: Humans; Infusions, Parenteral; Intraoperative Care; Liver Neoplasms; Mitomycin; Neoplastic Cells, Ci | 1992 |
Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C.
Topics: Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eosinophilia; | 1992 |
[Clinical studies on locoregional immunochemotherapy of peritonitis carcinomatosa].
Topics: Cisplatin; Humans; Immunotherapy; Infusions, Parenteral; Mitomycin; Pancreatic Neoplasms; Peritoniti | 1992 |
[Histological evaluation of intra-arterial infusion and systemic chemotherapy of pancreatic carcinomas].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 1992 |
Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined | 1992 |
[Portal blood levels of mitomycin C after intraperitoneal administration].
Topics: Humans; Infusions, Parenteral; Liver Neoplasms; Mitomycin; Pancreatic Neoplasms; Portal Vein | 1992 |
Isolated perfusion of pancreas with mitomycin C.
Topics: Amylases; Animals; Blood Glucose; Chemotherapy, Cancer, Regional Perfusion; Chromatography, High Pre | 1990 |
Evidence of effective multidisciplinary treatment for resectable pancreatic cancer from the viewpoint of the CA19-9 level.
Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Carcinoma; Combined Modality Therapy; Female; Humans | 1991 |
[Long-term arterial infusion chemotherapy combined with external irradiation therapy for unresectable pancreatic cancer--a case report].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Combined Modal | 1991 |
[Combination chemotherapy of HO-221, a derivative of benzoylphenylurea with various anticancer agents against human cancer xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Div | 1991 |
[Combination of a biscoclaurine alkaloid, cepharanthine, and anticancer agents: effects and mechanism in human gastric and pancreatic carcinoma cell lines].
Topics: Alkaloids; Antineoplastic Agents; Benzylisoquinolines; Cell Division; Doxorubicin; Drug Synergism; F | 1991 |
5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bili | 1991 |
Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay.
Topics: Breast Neoplasms; Carbazilquinone; Cisplatin; Colorectal Neoplasms; DNA, Neoplasm; Doxorubicin; Drug | 1990 |
[Methodological aspects on the histological evaluation of subrenal capsule assay (SRCA)].
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cyclophosphamide; Cyclosporins; Female; Fluoroura | 1990 |
Experimental study on multidisciplinary treatment of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Combined Modality Therapy; Cricetinae; Disease Model | 1990 |
[Clinical studies of in vitro chemosensitivity test evaluated by ATP assay of gastrointestinal cancer].
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Scree | 1990 |
Growth-inhibitory effect of combination chemotherapy for human pancreatic cancer cell lines.
Topics: Aclarubicin; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1990 |
Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1990 |
[Missile therapy of colorectal and pancreatic cancers--clinical trial of monoclonal antibody, A7-NCS, in 73 patients with colorectal and pancreatic cancers].
Topics: Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Colorectal Neoplasms; Doxorubicin; Drug A | 1990 |
[Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Hepatocellular; Combined | 1985 |
[Palliative treatment for unresectable cases of pancreatic carcinoma].
Topics: Adult; Aged; Gastroenterostomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Age | 1985 |
[Combination therapy with lentinan, mitomycin c, 5-fluorouracil and radiation--a case of long-term survival of pancreas cancer after palliative surgery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu | 1987 |
Effects of MAb BW 494/32 and rTNF-a/rIFN-g alone and in combination in nude mice bearing xenografts of human gastrointestinal/pancreatic carcinomas.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Gastrointestinal Neoplasms; Humans; Interfer | 1989 |
Combined therapy of xenografts of human pancreatic carcinomas with rTNF-alpha and mitomycin C.
Topics: Animals; Antigens, Tumor-Associated, Carbohydrate; Cell Division; Colorectal Neoplasms; Combined Mod | 1989 |
[Long-term arterial infusion chemotherapy in unresectable pancreatic cancer].
Topics: Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 1989 |
[Preventive effects of intra-arterial infusion chemotherapy of liver metastasis in non-resectable pancreatic cancer].
Topics: Alprostadil; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Humans; Infusions, Intr | 1989 |
Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Infusi | 1989 |
[Intra-arterial infusion chemotherapy in non-resectable pancreatic cancer using angiotensin-II and implantable drug delivery system].
Topics: Adenoma, Bile Duct; Adult; Aged; Aged, 80 and over; Angiotensin II; Antineoplastic Combined Chemothe | 1989 |
Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot study.
Topics: Activities of Daily Living; Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemothe | 1989 |
[Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla | 1987 |
[Antitumor effect of interferons with chemotherapeutic agents].
Topics: Antineoplastic Agents; Cell Line; Cells, Cultured; Cisplatin; Drug Therapy, Combination; Fluorouraci | 1986 |
[Effect of intratumor mitomycin-C injection on growth of homologously implanted pancreatic cancer in Syrian golden hamster].
Topics: Adenocarcinoma; Animals; Cricetinae; Instillation, Drug; Mesocricetus; Mitomycin; Mitomycins; Neopla | 1986 |
Enhanced chemosensitivity of cells from malignant effusions under condition of exposure to high temperature.
Topics: Ascitic Fluid; Breast Neoplasms; Cells, Cultured; Colonic Neoplasms; Colony-Forming Units Assay; Dox | 1986 |
[Comparative study with reduction rate of tumor and decrease rate of tumor markers as an effect of MMC on human cancer producing CEA and CA19-9 xenotransplanted in nude mice].
Topics: Animals; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Carcinoembryonic Antigen; Dru | 1987 |
[Anatomo-clinical conference. Hôpital de la Pitié-Salpêtrière. Case n. 2-1987. Anemia, thrombopenia and renal insufficiency in a patient treated for cancer of the pancreas].
Topics: Hemolytic-Uremic Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Pancre | 1987 |
[Subrenal capsule assay as a chemosensitivity test (III)--Comparison of host reaction, experimental chemotherapy and use of nude mice].
Topics: Animals; Breast Neoplasms; Cell Line; Drug Evaluation, Preclinical; Fluorouracil; Humans; Mice; Mice | 1987 |
[UFTM therapy in patients with unresectable pancreatic cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, In | 1987 |
Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorourac | 1988 |
Multidisciplinary treatment for resectable pancreatic cancer.
Topics: Aged; Combined Modality Therapy; Humans; Infusions, Intra-Arterial; Intraoperative Care; Middle Aged | 1988 |
[An experimental attempt to potentiate therapeutic effects of combined use of pulsing magnetic fields and antitumor agents].
Topics: Adenocarcinoma; Animals; Cell Division; Combined Modality Therapy; Cricetinae; DNA, Neoplasm; Electr | 1988 |
[Chemotherapy of pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Female | 1985 |
Cytology of solid and papillary epithelial neoplasms of the pancreas: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Papillary; Cytodia | 1988 |
[Clinical evaluation of implantable drug delivery system (Port-A-Cath) in cancer chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1988 |
Chemotherapy for advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Mitomycin; Mitomy | 1986 |
[Intra-arterial continuous infusion in patients with advanced and recurrent cancer of the digestive system].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 1985 |
[Multidisciplinary treatment of cancer of the pancreas].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Humans; Infusions, Intr | 1985 |
[Present state of the multidisciplinary treatment of pancreatic carcinoma].
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Humans; Mitomycin; Mitomycins; Pancreas; Pan | 1985 |
[Biliary and pancreatic excretion of mitomycin C, with special reference to the concomitant use of urokinase].
Topics: Bile; Duodenal Neoplasms; Humans; Mitomycin; Mitomycins; Pancreatic Juice; Pancreatic Neoplasms; Uro | 1985 |
[Intratumoral injection therapy of mitomycin C adsorbed to activated carbon particles under ultrasound guidance for pancreatic cancer].
Topics: Aged; Charcoal; Female; Humans; Male; Middle Aged; Mitomycin; Mitomycins; Pancreatic Neoplasms; Ultr | 1985 |